Identifying factors which maximise the lambing performance of hoggets: a cross sectional study

AIM: To identity perceptions of farmers with respect to advantages of hogget lambing and to identify optimal management strategies for hogget lambing used in New Zealand.

METHODS: A questionnaire was sent to 1,038 sheep farmers in New Zealand who had indicated their hoggets would be lambing in 2002. Information was gathered on the practice of hogget lambing in New Zealand, in particular on the numbers and breeds of hoggets and rams used, selection criteria used for hoggets, use of teasers (vasectomised rams), length of mating period, use of mating crayons, vaccinations, medications and mineral supplements given, level of feed offered, use of pregnancy scanning, management during pregnancy and lambing, number of lambs present at docking, and shearing policies for hoggets. Farmers were also asked to indicate the relative importance of five stated reasons for choosing to have their hoggets mated in 2002.

RESULTS: A total of 629 (60.6%) responses were incorporated in the analysis, and the average percentage of hogget lambing was 60%. Use of vaccinations, length of the mating period, number of rams used, breed of hogget, weight at mating, management during lactation, and shearing policy were associated (p<0.05) with the lambing performance of hoggets, in the multivariate analysis.

CONCLUSIONS: This study indicated that to ensure high lambing percentages (LP) in hoggets in New Zealand, sheep farmers should: vaccinate hoggets against toxoplasmosis and campylobacteriosis; utilise a 40-day mating period; use 2.6–3.5% of rams during mating; incorporate Finn or East Friesian genetics; ensure liveweights at mating are as high as possible; manage single- and multiple-bearing/-rearing hoggets separately during the lambing and lactation periods; and shear hoggets pre-mating.     

Clinical Use of Fatty Acid Supplements in Dogs

Abstract— Fatty acids in membrane phospholipids are metabolized by cellular enzymes into a variety of eicosanoids that function in the regulation of normal physiology and serve as mediators of inflammation. Fatty acid supplements can alter the types of eicosanoids produced. Many investigations using fatty acids in the treatment of nutritional deficiencies, seborrhea, atopic dermatitis, cardiovascular, neoplastic, ocular and musculoskeletal diseases of dogs have been conducted over the past decade. Additional studies are needed to determine the optimal levels of linoleic acid, gamma-linolenic acid and/or eicosapentaneoic acid in the diets of dogs for the maintenance of normal homeostasis and for the treatment of inflammatory, degenerative and neoplastic diseases.     

Growth of body weight and manipulation of food motivation

Consideration was given to the possible use of individual growth curves to estimate ad libitum-feeding weights as part of technique for producing specified degrees of food deprivation. In heterozygous animals, this possibility was found to be feasible but limited by the occurrence of discontinuous growth functions.     

A survey of granulomatous and neoplastic diseases of equine skin in north Queensland

SUMMARY A survey of granulomatous and neoplastic diseases of the skin of horses of tropical north Queensland was carried out during the period 1970–1980. Of 338 horses affected, 46.4% suffered from equine fibrosarcoma (sarcoid), 30.2% from phycomycosis, 7.4% from squamous cell carcinoma, 6.8% from other tumours, 4.7% from cutaneous habronemiasis and 4.4% from exuberant granulation tissue. Most specimens were submitted during the first half of the year after the wet monsoonal season and significantly more diseases originated during the first quarter. There were minor variations with breed, age and sex susceptibility between each disease group. Most lesions were found on the legs and head although other parts of the body were also affected. The size and anatomical distribution of lesions varied with each disease. When the results of this survey were compared with reports from southern Queensland as well as from Florida and the United Kingdom, major differences between localities were observed. Some reasons for these differences are discussed.     

Biologic activity of dirlotapide, a novel microsomal triglyceride transfer protein inhibitor, for weight loss in obese dogs

Dirlotapide is a novel microsomal triglyceride transfer protein inhibitor intended for the treatment and management of obesity in dogs. The biologic effects of dirlotapide, weight loss, decreased food intake, increased fecal fat, decreased serum cholesterol, and body composition, were evaluated in a controlled, blinded study. Sixteen obese beagles were randomized to treatment with placebo ( n  = 4) or dirlotapide ( n  = 12) following a 2-week acclimation period in which baseline data were collected. The dirlotapide dose, adjusted to produce weight loss for 3 months and then stabilize body weight for 1 month (weight management), produced a significant difference (expressed as a percentage of baselines) in weekly weight loss, food intake, fecal fat, serum cholesterol concentration, and body composition (measured by dual energy X-ray absorptiometry) compared with placebo treatment ( P  < 0.05). The initial dirlotapide dosage of 0.5 mg/kg (10 times the initial label dose) resulted in a high rate of weight loss (3.3% weekly) and anorexia, emesis, and loose stools for some dogs. A 25% dose reduction (mean dosage: 0.36 mg/kg) followed by biweekly 25% dose adjustments based on individual weight loss, produced 1–2% weekly weight loss and total weight loss of 18.8% in 12 weeks at a final mean dosage of 0.41 mg/kg (range: 0.15–0.60); a dosage range of 0.10–0.34 mg/kg stabilized body weight. Body weight changes for placebo-treated dogs were −0.8% to +0.9% weekly; total weight gain during the weight loss phase was 10.6%. No apparent change in food intake, percentage of fecal fat, and serum cholesterol was observed in the placebo group. Food intake and body weight increased when dirlotapide was discontinued. Dirlotapide produced weight loss by both reducing appetite (about 90% of the weight loss activity) and by increasing fecal fat excretion (about 10% of the weight loss activity).